BridgeBio Pharma Inc header image

BridgeBio Pharma Inc

BBIO

Equity

ISIN null / Valor 48204826

NASDAQ (2026-11-04)
USD 77.89+5.21%

BridgeBio Pharma Inc
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

BridgeBio Pharma Inc. is a publicly traded biopharmaceutical company (Nasdaq: BBIO) based in Palo Alto, California, that develops targeted therapies for genetically defined diseases and select cancers. It builds a diversified pipeline of discovery- and development-stage programs—often organized into focused operating subsidiaries—using genetic and biomarker data to guide patient selection and clinical strategy, and advancing candidates through clinical trials toward regulatory approval and commercialization through a mix of in-house development, partnerships and licensing. The company’s business model emphasizes translating genetic insights into precision medicines for rare and oncology indications while managing program-specific risk and capital allocation across its portfolio.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

26.9%1Y
170%3Y
51.4%5Y

Performance

46.5%1Y
51.1%3Y
93.9%5Y

Volatility

Market cap

15173 M

Market cap (USD)

Daily traded volume (Shares)

5,552,354

Daily traded volume (Shares)

1 day high/low

27.93 / 27.25

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
2.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.00
Josh Bentley
UK, 19 Oct 2026
star star star star star
Real potential for a good run up to PDUFA.

EQUITIES OF THE SAME SECTOR

Alcon Inc.
Alcon Inc. Alcon Inc. Valor: 43249246
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.75%CHF 63.28
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
6.28%CHF 107.40
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.19%CHF 401.80
AEVIS VICTORIA SA
AEVIS VICTORIA SA AEVIS VICTORIA SA Valor: 47863410
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%CHF 14.30
PolyPeptide Group Ltd
PolyPeptide Group Ltd PolyPeptide Group Ltd Valor: 111076085
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.93%CHF 41.35
Basilea Pharmaceutica Ltd, Allschwil
Basilea Pharmaceutica Ltd, Allschwil Basilea Pharmaceutica Ltd, Allschwil Valor: 1143244
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.96%CHF 73.70
DocMorris Ltd
DocMorris Ltd DocMorris Ltd Valor: 4261528
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.07%CHF 16.24
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A. Valor: 2791431
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.91%CHF 9.40
Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
11.14%USD 39.41
Fagron SA
Fagron SA Fagron SA Valor: 3425437
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.13%EUR 23.95